Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Prostate Cancer (BRCA1/2, Homologous Recombination Repair Gene Alterations, Microsatellite Instability/Mismatch Repair, Tumor Mutational Burden)

Biomarker-targeted therapy has shown a clear survival benefit in individuals with metastatic prostate cancer. Typically, the evaluation of biomarker status requires tissue biopsy. Circulating tumor DNA (ctDNA) (also known as liquid biopsy) is proposed as a non-invasive alternative.